Dual PD-1 and LAG-3 blockade was recently approved in advanced or unresectable melanoma in 2022, and there are currently numerous clinical trials evaluating the combination across a diversity of solid tumor types, including non-small cell lung, colorectal, hepatocellular carcinoma, and resected melanoma. Here, LAG3 is linked to melanoma.